Sanofi Starting US Cialis OTC Actual Use Study Soon While Tamiflu Switch Progress Delayed

French Pharma Reports €1.33Bn Q1 Consumer Health Sales Helped By Price Increases

After 118.2% cough/cold sales growth leads 17% overall consumer business growth, Sanofi points to still stronger days ahead while keeping the business under the same roof with its pharmaceutical and vaccine divisions.

• Source: Sanofi

Sanofi reports an historic step for the potential first US OTC switch of an erectile dysfunction drug while refusing even the slightest nod toward an imminent spin-out of its consumer business, a key driver in its 8.6% net sales growth for its latest quarter.

After cough/cold sales led the way in the first quarter at 118.2% growth for 17% overall consumer business growth to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

SkinBioTherapeutics Raises Funds For Supplement Development And Launch

 
• By 

UK-based firm will use the capital to launch its AxisBiotix skin health supplements in Superdrug stores and to develop new product formats.

Zentiva Strikes Deal With Aboca To Expand CHC Offering

 
• By 

Czech Republic's Zentiva snaps up Aboca portfolio adding supplement brands marketed in European countries such France, Italy and Spain.

Poland’s Formeds Acquired By Private Equity

 
• By 

Enterprise Investors takes 77% stake in Polish clean-label dietary supplements manufacturer Formeds.

Urgo Makes Moves In Poland And Belgium

 
• By 

French consumer health player Urgo has added to its dietary supplements offering with separate deals in Poland and Belgium.

More from Business